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Summary
Purpose: Genetic characteristic of cytokines may influence 
cervical intraepithelial neoplasia (CIN) and cervical cancer 
(CCa) susceptibility. We analysed an association of IL-10-
592 A/C, IL-4R I75VA/G polymorphisms with susceptibility 
to human papillomavirus (HPV) positive CIN and CCa. 
Methods: Using multiplex PCR- SNaPShot analysis, 134 
cases (HPV positive CINs and CCa) and 113 controls (HPV 
negative NILM) were genotyped for these two cytokine 
variants. 
Results: Data analyzed using odds ratio (OR) and chi-
square (x2) test showed that the frequency of CC of IL-10-592 
genotype was significantly higher in cases (67.2%) than in 
controls (49.6%) [CC vs CA+AA; p=0.005, OR=2.08 (95%CI: 
1.24-3.49)] as well as the allelic frequency of major C allele 
(82.1%) in cases than in controls (72.6%) [p=0.01, OR=1.73 
(95%CI: 1.13-2.66)]. Furthermore, AA genotype of IL-4RI75V 
had significantly lower frequency in CIN1 (25.0%) compared 
with CIN2+ group (30.8%) (p=0.03, OR=0.39, 95%CI: 0.14-
1.11) after the stratifications of the cases in low grade and 
high grade with CCa as separate groups. 
Conclusion: We concluded that IL-10-592 A/AA variant 
indicates a protective role in cervical cancer development and 
the GG genotype of IL-4RI75V conferred protection against 
progression of CIN1 to CIN2+ or CCa among women from 
Republic of North Macedonia.
Key words: cervical cancer, cervical intraepithelial lesions, 
IL-4R, IL-10, polymorphisms
Introduction
 Cervical cancer is the second most frequent 
malignant disease in women worldwide and the 
fifth most deadly malignancy in mortality from 
cancer among females in developing countries [1]. 
HPV is the most important etiological factor of ini-
tiation of cervical intraepithelial abnormalities but 
still the majority of HPV infections are spontane-
ously resolved and do not contribute to progression 
to disease. 
 The host variations in immune regulating 
genes, such as cytokine genes, can influence the 
outcome of HPV infection as well as CIN progres-
sion. Cytokines play a crucial role in the regulation 
of key pathways of immunity and the balance be-
tween cell-mediated (Th1) and humoral (Th2) re-
sponsiveness. Th1 cells drive cellular immunity to 
fight intracellular pathogens including viruses and 
to remove cancer cells, whereas Th-2 cells control 
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humoral immunity by up-regulating antibody pro-
duction to protect against extracellular pathogens 
[2,3]. 
 Interleukin 10 (IL-10) is a key cytokine that 
determines viral clearance or viral persistence [4,5]. 
It is a multifunctional Th2-cytokine that acts as an 
immune response modulator and anti-inflammato-
ry agent in HPV infection associated with of E6 and 
E7 viral oncoproteins production [6,7] and it also 
interferes in the process of carcinogenesis [8,9]. 
Some studies showed that its higher production 
related to different IL-10 genetic characteristics has 
immunosuppressive effect and support viral persis-
tence [5,10,11]. Single nucleotide polymorphisms 
(SNPs) within the promoter of IL-10 gene were re-
ported to be associated with HPV persistence and 
CIN progression by changing the immune response 
to HPV and modifying the risk for CCa develop-
ment. The variants in this region have been shown 
to be associated with differential gene transcription 
that can produce low, medium or high amount of 
gene product [11,12] and different cell clearance 
from HPV infection [13] followed by susceptibility 
to infections [14] in some malignancies.
 Additionally, Interleukin 4 (IL-4) is another im-
mune factor that may influence the course of the 
disease exerting its biological effects via signalling 
through its receptor, IL-4R. Polymorphism in IL-4R 
I75V could have influence in HPV viral persistence 
as well, based on assumption that it could alter 
Th1/Th2 balance, rising Th2 response. A recent re-
port showed that autocrine secretion of IL-4 alters 
the apoptosis [15], so IL-4 interaction with its re-
ceptor variant could be additional mechanism that 
influences the cervical carcinogenesis, changing 
the rate of apoptosis. 
  Therefore, we conducted a case-control study 
carried out to find whether IL-10-592 and IL-4R 
I75V polymorphisms associate with HPV positive 
CIN1+ and CCa in a group of women from Republic 
of North Macedonia.
 For this purpose we used SNapShot method 
and we designed primers for multiplex reaction 
guided by previous scientific experience [16-18]. 
Methods 
Patient selection
 A total of 247 women who underwent cervical can-
cer screening, both with cytological and HPV testing of 
cervical specimens and/or underwent surgical treatment 
from private gynaecological clinics in Skopje and the 
University Clinic for Obstetrics and Gynecology of the 
Medical Faculty in Skopje, were approached to partici-
pate in this study. The inclusion criteria for the cases 
were to be twice successively HPV positive in a period 
of 12 months and have histologically confirmed CIN1+ 
and for control group to be HPV negative NILM. The 
cytological and/or histological status was confirmed by 
pathological diagnosis on cervical swabs and surgical 
specimens, respectively. The cytological diagnosis was 
done by cytopathologists using the Bethesda classifi-
cation system. Histology was performed on specimens 
dbSNP Reference sequence Genome position Transcript cDNA Protein sequence Aa* Trivial name
rs1800872 NC_000001.10 g.206946407T>G NM_000572.2 c.-627A>C  IL-10-592 C/A
*Aa: amino acid change
Table 1. Genetic characteristics of the analyzed polymorphisms
Gene variant * 5’-3’ base pair PCR-fragment
IL-10-592 C/A F GGGGTCATGGTGAGCACTAC 230
R CAAGCAGCCCTTCCATTTTA
IL-4R-I75V G/A F CCCCAGATCTGTCCTCACAT 242
R AGCCCACAGGTCCAGTGTAT
*primer orientation
Table 2. Primers used in multiplex reaction in detection of the four SNPs (rs1800872, rs1805010)
Gene polymorphism 5’-3’ Bp# P* SNP E** C(µM)
IL-10-592 C/A CAGAGACTGGCTTCCTACAG 20+16 (C) reverse G/T 36.8/37.0 2
IL-4R I75V G/A GCCTCCGTTGTTCTCAGGGA 20 (C) reverse C/T 28.5/30.7 2
#Bp: base pairs, *p: primer orientation, **E: electrophoregram position (referent/variant), C(μM): concentration in μM
Table 3. Primers for single-nucleotide primer extension reaction 
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collected by a colposcopy-directed biopsy and/or cone 
specimens collected by loop excision procedure in pa-
tients where it was indicated or on surgical specimens. 
HPV DNA and SNP typing were done in the Laboratory 
for Virology and Molecular Diagnostics of the Institute 
of Public Health of Republic of North Macedonia (IP-
HRNM) and in the Research Center for Genetic Engi-
neering and Biotechnology (RCGEB), Academy of Sci-
ences and Arts of Republic of North Macedonia (MASA). 
The pathologists involved in the cytological and his-
tological assessments were not involved in testing for 
HPV. Signed informed consent was obtained from all 
individual participants included in the study. The control 
group consisted of 113 HPV and cytologically NILM 
findings, while the case group consisted of 134 HPV 
positive women with histologically confirmed CIN or 
CCa. The median age of study participants was 42.6 years 
(range 21-68). The study was approved by the IPHRNM 
Ethics Committee.
DNA isolation
 QIAamp® DNA Blood Mini Kit (Qiagen GmbH, 
Hilden, Germany) was used for DNA extraction from 
peripheral blood (case group) and cervical swabs (control 
group) according to the manufacture’s instructions.
HPV detection
 Cervical specimens for nucleic acid analyses were 
collected with a cervical brush via standard procedures. 
HPV typing was performed using HPV4ACE 4 Screening 
(Seeplex, Seegene, Korea) on DNA isolated from cervical 
swabs. 
Primer design, SNP genotyping
 For SNPs analysis we used exfoliated cervical cells 
obtained from cervical swabs specimens from the con-
trol group and CIN1 patients. Blood specimens were ob-
tained from CIN2+ and CCa patients. The primers were 
designed using primer design software - Primer3Plus 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/prim-
er3plus.cgi). Secondary structures and potential primer 
dimers were predicted using the PriDimerCheck (http://
biocompute.bmi.ac.cn/MPprimer/primer_dimer.html). 
The characteristics of selected polymorphisms are pre-
sented in Table 1. 
 Multiplex polymerase chain reaction (PCR) followed 
by single-nucleotide primer extension assay were done 
for SNP genotyping. PCR primers were designed to give 
amplicons with different fragment sizes (Table 2). 
 The mutation-specific primers were 5’ tailed with 
a poly-C sequence to produce extension products of 21 
and 44 nucleotides long allowing separation by capil-
lary electrophoresis (Table 3). After SNaPShot reaction, 
SAP-inactivated single-nucleotide extension reaction, 
diluted with HiDi Formamide (Life Technologies, Carls-
bad, CA, USA) and supplied with 0.5 μl GeneScan 120 
LIZ Size Standard (Life Technologies) was denatured at 
95°C for 5 min and loaded onto an ABI PRISM 3130 Ge-
netic Analyzer (Life Technologies). Extension products 
were visualized and analyzed using GeneScan 4.0 (Life 
Technologies) (Figure1). Initial validation of the method 
was performed against DNA sequencing of the amplified 
regions.
Statistics
 All statistical analyses were done using SPSS soft-
ware 1.0 (IBM SPSS Chicago, IL, USA). The possible as-
sociation between polymorphisms and stage of cervical 
lesions was done using Pearson x2 test and the Fisher 
exact test, where indicated. The significance of associa-
tion was assessed by odds ratio (OR) and 95% confidence 
interval (95%CI). Multivariate binary logistic regression 
analysis was used to examine the effect of the studied 
polymorphisms after adjusting for age and tobacco 
smoking. Deviation from Hardy-Weinberg equilibrium 
(HWE) in the studied groups was examined by x2 test. 
P value <0.05 was considered as statistically significant 
for both analyses.
Results
 An association was observed between SNP 
IL-10-592C/A (rs1800872) and IL-4RI75VA/G 
(rs1805010) with HPV positive cervical lesions and 
CCa. The alleles in the control group were within 
HWE. The characteristics of the women tested af-
ter gynaecological examinations are presented in 
Table 4.
 For further association analysis the study 
group was stratified in groups based on the grade 
of cervical lesions: all cases CINs and CCa in group 
C1 (n=134); CIN2+ and CCa in C2 group (n=94: 20 
CIN2, 37 CIN3, 17 Ca in situ, 20 microinvasive and 
invasive cervix uteri) and C3 group (n=40) consist-
ed only of CIN1. 
 The results from the SNP analyses indicated 
an IL-10-592C/A association with HPV positive CIN 
and CCa. The allelic frequency of major C allele was 
higher within C1 and C2 group (82.1 and 83.0%, 
respectively) compared to N group (NILM and no 
HPV infection) (72.6%): [p=0.01, OR=1.73 (95%CI: 
1.13-2.66)] and [p=0.01, OR=1.8 (95%CI: 1.1-3.0)], 
respectively (Table 5).
Figure 1. Electrophoregram after multiplex PCR followed by 
SNaPShot analysis on capillary electrophoresis. The Figure 
shows heterozygous AG genotype for IL-4R175V and ho-
mozygous CC genotype for IL-10-592.  
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 Moreover, the frequency of CC genotype was 
significantly higher in all cases - C1 group (67.2%) 
and in C2 group (CIN2+ and CCa) (70.2%), compared 
to the N group (49.6%): [CC vs CA+AA; p=0.005, 
OR=2.08 (95%CI: 1.24-3.49)] and [CC vs CA+AA; 
p=0.002, OR 2.39 (95%CI; 1.35-4.27], respectively 
(Table 6). Similar results for all cases compared 
to the controls were observed after adjustment for 
age and tobacco smoking. Summary of allele and 
genotype distribution between cases and controls 
is shown in Figure 2. 
 The results from IL-4RI75V polymorphism 
showed that the allele frequencies of 134 case sub-
jects [A (17.9%) and G (82.1%)] were not signifi-




Tobacco smoking 40 16.2
No smoking 207 83.8
NILM, no HPV 113 45.7
Histology
CIN1 40 16.2
CIN2, CIN3 57 23.1
Ca in situ 17 6.9
Ca micro invasive and invasive 20  8.1
HPV type In CIN1 (%) In CN2+, CCa (%) Total
HPV 16 and/or 18 6 (15.0) 58 (61.7) 64 (47.8)
Other High risk type 24 (60.0) 20 (21.3) 44 (32.8)
Multiple infections 10 (25.0) 16 (17.0) 26 (19.4)
Total  40 (100.0)  94 (100.0) 134 (100.0)









p1(x2) p2(x2) p3 (x2) p4 (x2)
IL10-592  A 48 (17.9) 32 (17.0) 16 (20.0) 62 (27.4) 0.01 0.01 0.18 0.56
C 220 (82.1) 156 (83.0) 64 (80) 164 (72.6)
IL-4R  A 145 (54.1) 108 (57.4) 37 (46.3) 117 (51.8) 0.60 0.30 0.39 0.1
G 123 (45.9) 80 (42.6) 43 (53.7) 109 (48.2)
p1: association C1 vs N; p2 (C2 vs N); p3 (C3 vs N); p4 (C3 vs C2)
Table 5. Characteristics of study group (age, histological results and HPV type presence)
Figure 2. Summary from comparison of allele and genotype frequencies in cases and controls for both polymorphisms.
A: IL-10-592 C allele frequency compared to A allele in cases and controls, p=0.01; B: IL-10-592 CC genotype frequency 
compared to CA and/or CA+AA genotypes in cases vs controls, p=0.005. General distribution of allele and genotype frequen-
cies in IL-4R 175V doesn’t show statistically significant difference between cases and controls. 
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cantly different from those of 113 control subject [A 
(27.4%) and G (72.6%;Table 5). However, after anal-
ysis of stratified cases in 3 groups we found that GG 
genotype has significantly higher frequency in C3 
(32.5%) than in C2 (16.0%) group [recessive model: 
GG vs АG+АА; p=0.03, OR=0.39 (95%CI: 0.14-1.1)]. 
The frequency distribution of different genotypes 
for the IL-4RI75VA/G polymorphism is presented 
in Tables 6 and 7.
 The OR and 95% CI values only from the sig-
nificant association analysis done with Pearson x2 
test, are presented in Table 8. For the other results 
we show only the p value as indicator of signifi-
cance in the previous Table. 
SNPs Genotype C1 (%) n (%) p (x2) OR 95% CI p*(x2) OR* 95% CI
IL10-592 C/A CC 90(67.2) 56 (49.6) ref - - ref - -
CA 40(29.9) 52 (46.0) 0.005 0.47 0.28-0.81 0.006 0.47 0.27-0.80
AA 4 (2.9) 5 (4.4) 0.3 0.49 0.12-1.9 0.29 0.48 0.12-1.90
AC+AA/CC 44(32.8)/90 (67.2) 57 (50.4)/56 (49.6) 0.005 0.48 0.28-0.8 0.006 0.48 0.27-0.81
AA/AC+CC 4 (2.9)/130 (97.1) 5 (4.4)/108 (95.6) 0.39 0.66 0.17-2.53 0.37 0.64 0.15-2.5
IL-4R I75V G/A GG 28 (20.9) 24 (21.2) 0.63 0.83 0.4-1.7 0.63 1.19 0.57-2.47
GA 67 (50.0) 61 (54.0) 0.43 0.78 0.4-1.4 0.85 0.93 0.49-1.8
AA 39 (29.1) 28 (24.8) ref - - ref - -
AG+AA/GG 106 (79.1)/28 (20.90) 89 (78.8)/24 (21.2) 0.90 1.02 0.55-1.88
AA/AG+GG 39 (29.1)/95 (70.9) 28 (24.8)/85(75.2) 0.44 1.2 0.7-2.19
*p: chi square value and odds ratio (OR) value adjusted by age and tobacco smoking. Bold numbers denote statistical significance.
Table 6. Genotype frequencies of different SNPs and results after statistical analyses using x2 test and Odds ratios (OR) 







p 2(x2) p 3(x2) p 4(x2)
IL10-592 CC 66 (70.2) 24 (60.0) 56 (49.6) Ref Ref Ref
CA 24 (25.5) 16 (40.0) 52 (46.0) 0.01 0.37 0.13
AA 4 (4.3) 0 5 (4.4) 0.6 0.6 0.11
AC+AC /CC 28 (29.8)/66 (70.2) 1640.0)/24 (60.0) 57 (50.4)/56 (49.6) 0.002 0.25 0.24
AA/CC+CA 4/90 0/40 5/108 0.6 0.2 0.08
IL-4R I75V GG 15 (16.0) 13 (32.5) 24 (21.2) 0.23 0.4 0.08
GA 50 (53.2) 17 (42.5) 61 (54.0) 0.47 0.59 1
AA ref 29 (30.8) 10 (25.0) 28 (24.8) Ref Ref Ref
AG+AA /GG 79 (84.0)/15 (16.0) 27(67.5)/13 (32.5) 89 (78.8)/24 (21.1) 0.40 0.15 0.03
AA/GG+GA 29 (30.8)/65 (69.2) 10 (25.0)/30 (75.0) 28 (24.8)/85 (75.2) 0.40 0.61 0.5
n-total 94 (100) 40 (100) 113 (100)
p: Values obtained by chi-square test, C: case group, N: control group, n: number. p2 (association C2 vs N); p3 (C3 vs N); p4 (C3 vs C2). Bold 
numbers denote statistical significance.
Table 7. Results after stratification in groups depending of grade of the lesions.
SNPs Comparison Model p(x2) OR 95% CI
IL-10-592 Cases/controls allelic A vs C 0.01 1.73 1.1-2.6
Cases/controls heterozygous CA vs CC 0.005 0.47 0.3-0.8
Cases/controls dominant CC vs AC+AA 0.005 2.08 1.2-3.4
CIN2+, CCa /controls allelic A vs C 0.01 1.8 1.1-3.0
CIN2+,CCa /controls heterozygous CA vs CC 0.01 3.5 1.4-4.6
CIN2+CCa/controls dominant CC vs CA+AA 0.02 2.4 1.3-3.2
IL-4R I75V CIN2+, CC/CIN1 recessive GA+AA vs GG 0.03 0.4 0.1-1.1
Table 8. Significant statistical associations between the SNPs and the grade of CIN lesions or CCa presented by OR and 
95% confidence interval
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Discussion
  The IL-4 and IL-10 are cytokines known to be 
involved in anti-inflammatory processes which are 
potentially cancer-promoting. They have antiangi-
ogenic function (potentially cancer-inhibiting fac-
tor) as well, so their role in cervical cancer may be 
dual [7]. In fact, there are many contradictory stud-
ies about the association of the variants of these 
2 genes with HPV and cervical cancer, so we did 
an investigation whether Northern-Macedonian 
women with particular genotypes are at risk for 
HPV positive CIN or CCa. 
 Two E6 and E7 viral oncoproteins of high risk 
HPV types, play important role in the malignant 
transformation of cervical cancer cells and during 
their high activity, IL-10 influences the promotion 
of tumor growth [7]. Based on this knowledge, for 
further analyses, we selected only HPV persistent-
ly infected CIN as cases that are theoretically at 
higher risk for progression to CIN2+ or CCa. The 
IL-10 gene promoter is highly polymorphic and 
different variants of this promoter gene have im-
plication on its activity. Some important SNPs in 
the promoter’s region are supposed to influence 
the transcription of IL-10 mRNA and its expres-
sion in vitro (rs1800896, rs1800871 and rs1800872) 
[10,19-21] and have been identified in many dis-
eases. Positive correlation of rs1800872 polymor-
phisms with HPV and cervical cancer susceptibil-
ity was observed, especially in Asian populations 
[22]. These polymorphisms could have influence 
on the immune response to HPV and could modify 
the risk for CCa. We analyzed this polymorphism 
based on the model that IL-10-592 A variant is as-
sociated with lower IL-10 expression [23,24]. The 
higher expression leading to higher IL10 (related 
to CC genotype) is an event that may support the 
immunosuppressive effect of IL-10 and the onset 
of persistent infection.
 Another suggested mechanism is that E6 and 
E7 oncoproteins binding to the SP1 transcription 
factor of TGFb promoter, enhance the genetic reg-
ulation through GGGGCGG consensus sequence 
located on 180-172 nucleotides from TGF-β gene 
[25]. According to this finding and according the 
study of Torres-Proveda et al [26], E6 and E7 in-
crease the regulation of IL-10 expression resulting 
in lower IL-10 load and support the thesis that A 
allele carriers have two-fold higher risk for cervical 
cancer (lower blood concentration of IL-10). The 
exact mechanism of IL-10 CC variant influence on 
CIN and CCa development and HPV persistence is 
still unknown and left to be resolved.
 Our results are similar with the results ob-
tained in Indian and Asian populations [27-29] and 
from studies which indicated that the CC genotype 
is the risk factor for CIN and CCa, and the vari-
ant A allele and variant homozygote AA genotype 
have protective effects. We did not measure the 
IL10 blood concentration, we only assumed that 
CC genotype, as higher inducer of IL10, could have 
influence on cervical lesions. 
 In our study the frequency of CC genotype was 
confirmed to be significantly higher in all cases 
and, after stratification of the cases in two addi-
tional groups, significant association was found 
within CIN2+ and CCa group too. The different re-
sults regarding C variant as a protective variant in 
some populations [22] and a risk for North Mac-
edonian women might be explained with possible 
influence of different genetic or epidemiological 
factors that were not analysed in this study. Differ-
ent and inconclusive results are reported in other 
studies too [9,20,26,30,31]. This inconsistency 
could be also explained by the differences in study 
design and/or different genetic background of the 
population examined. Different allelic frequency 
of these alleles in different populations could be a 
factor for reaching different conclusion as well: in 
Asian population, the IL-10-592 A allele frequency 
is 0.87% which is significantly higher than in Eu-
ropean population (0.31%; p<0.001) [28]. 
 Finding that CC genotype is associated with 
significantly higher risk for CCa in North Macedo-
nian women shows that different biological mecha-
nisms could have influence in this association as 
well as the impact of the influence of epidemiologi-
cal factors.
 Regarding IL-4R variant, it is well known that 
its interaction with IL-4 ( Th2 cytokine) has impor-
tant role in the immune response and this IL-4/IL-
4R signalling pathway is a strong promoter of pro-
metastatic phenotypes in epithelial cancer cells, 
including enhanced migration, invasion, prolifera-
tion and lower survival [32]. 
 The IL-4R I75V polymorphism (rs1805010) 
A/G located in gene coding for α chain of the re-
ceptor, described as ‘gain-of-function’ mutation, 
results from substitution of isoleucine for valine 
(I75V) in the extracellular domain of IL-4Rα subu-
nit. A recent study showed that this variant was as-
sociated with enhanced receptor sensitivity to IL-4 
and this enhanced IL-4 signalling influences the 
promotion of a sustained phosphorylation, leading 
to abnormally active STAT6 transcription factor, 
even upon withdrawal (stopping) IL-4 stimulation 
[33]. 
 On the other hand, 75V variant could contrib-
ute to CCa development through its effect on Th1/
Th2 balance that can result in higher HPV and CCa 
susceptibility. This is based on the evidence that 
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cell mediated immunity, especially Th1, is the most 
important for HPV clearance [34]. 
 Thus, we hypothesised that the 75V variant 
could be linked to a TH2-based response and as-
sumed that it could influence viral persistence or 
progression due to the effect on Th1/Th2 balance 
that lead to increased susceptibility to cervical can-
cer. As it is already known, IL-4 can inhibit the 
differentiation of Th1 lymphocytes and downregu-
late the immune response of immune cells against 
malignant cells enabling tumor cells surveillance 
[35]. Still no scientific evidence confirmed that 
Th1/Th2 cytokines balance is the result of genetic 
characteristics. 
 Up to now only few studies have analysed an 
association of this variant with CCa susceptibility. 
Some studies of IL-4RI75V variant showed its as-
sociation with elevated risk for IgE production in 
cell lines [36] and in human immunodefinciency 
virus (HIV) positive carrier that leads to slow pro-
gression from HIV positivity to AIDS [37]. Carriers 
of this SNP also have higher risk for an erosive ill-
ness in rheumatic arthritis patients [38]. A Swedish 
study [39] concluded that IL-4R 75V variant is more 
frequent in CCa cases than in controls and they 
examined two additional SNPs in IL-4R: Q576R 
and V64I polymorphisms, that showed not be im-
portant for CCa development either individually 
or after analyzing the haplotypes. Another Asian 
study [40] provided opposite results, showing that 
the carriers of this polymorphism are less suscep-
tible to CCa in this population. 
 Our study showed an association between AA 
genotype (75I-variant) and progression of HPV-pos-
itive CIN1 to higher grade CIN2+ or CCa, and GG 
genotype (75V variant) may have a protective role 
in the progression of CIN1 to CIN2+ and CCa, but 
there was no evidence of any association between 
this polymorphism and initiation of HPV-positive 
CINs and cervical cancer. Preliminary results of 
our study suggest that IL-4R I75V G/A might be a 
good marker for assessing this progression.
 Our results for IL-10-592 and IL-4R 175V vari-
ants and their association with HPV positive CIN 
and CCa were obtained only from clinically defined 
factors and the power for explanation the biologi-
cal mechanism is limited and its functional rela-
tion remains unsolved. Furthermore, for proper 
evaluation of the importance of this association, 
explanation of the exact functional mechanism is 
necessary.
 Confirmation of the prognostic value for these 
cytokine variants needs inclusion of additional epi-
demiological and biological risk factors in more 
comprehensive studies with larger study groups.
Conclusion
  To our knowledge, this is the first study to 
report an association between IL-10- SNP592 C/A 
and IL-4RI75V A/G polymorphisms and the risk 
of CCa and CIN in women from Republic of North 
Macedonia, which indicates these genotypes could 
be used as predictive markers. Still, further epide-
miologic investigations involving larger studies 
and control groups with wider ethnic background 
should be conducted to explain the conflicting re-
sults and determine whether these variants are risk 
factors alone or if additional factors, such as expo-
sure to dietary carcinogens, smoking, using con-
traceptives or factors influencing IL and cytokine 
production could interfere with this association. 
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